Semaglutide (GLP-1 Agonist)
Worth trying, BioHarmony verdict
BioHarmony score 5.9 out of 10
Semaglutide is a prescription GLP-1 receptor agonist that produced 14.9% mean weight loss in STEP-1 and cut 3-point MACE by 20% in SELECT, but the 5.5-6.0/10 score holds because benefits often require indefinite use and rare severe harms remain unresolved.
Read full reportWhat is Semaglutide (GLP-1 Agonist)?
Semaglutide is a prescription GLP-1 receptor agonist used for type 2 diabetes, chronic weight management, cardiovascular risk reduction in adults with established CVD and overweight or obesity, and newer metabolic indications such as noncirrhotic MASH with fibrosis. In practice, semaglutide is best known as Ozempic for type 2 diabetes, Wegovy for obesity and cardiometabolic risk reduction, and Rybelsus as the oral tablet.
From the BioHarmony report, reviewed Sep 8, 2026.
Saved on this device only.
How it is thought to work
Activates GLP-1 receptors in pancreatic beta cells, appetite-regulating hypothalamic circuits, and the GI tract, increasing glucose-dependent insulin secretion, reducing glucagon, slowing gastric emptying, and suppressing appetite.
Safety watch-outs
- Persistent vomiting or dehydration
- Severe abdominal pain
- Blood in stool or black stool
- Symptoms of pancreatitis: severe upper abdominal pain radiating to back
Full risk profile in the BioHarmony report.
Dosing as published
Source-reported figures only. This page does not calculate a personal dose.
Working with a vial? The reconstitution calculator covers mixing math, not dosing advice.
More reported protocols
MembersMembers can compare additional reported doses, schedules, and preparation notes.
Educator coverage (3)
Attributed viewpoints, separate from primary research.
- My Top Peptide Stack for Mental Clarity & Muscle Repair Alex Kikel,
- Semaglutide Vs Tirzepatide Vs Reta A Critical Data Analysis Hunter Williams,
- Why Am I Not Losing Weight on Semaglutide? Jay Campbell,
Co-studied relationships
These entries name compounds evaluated together in a human study. They are not instructions to combine treatments.
Cagrilintide + semaglutide (CagriSema)
A randomised human trial evaluated this fixed combination against its component therapies. That makes it a co-studied relationship, not a DIY pairing or a recommendation to combine medicines.
REIMAGINE 2 randomised trial, 2026Trust & sourcing
- Last revieweddone
- Next reviewupcoming
FDA-approved semaglutide products include the Ozempic, Rybelsus and Wegovy brands. FDA separately warns that compounded injectable versions have caused dosing errors, including overdoses requiring hospitalization.
Primary sources
- FDA alert on dosing errors associated with compounded injectable semaglutide products U.S. Food and Drug Administration,
- Wegovy (semaglutide) prescribing information DailyMed, U.S. National Library of Medicine,
Related peptides for weight & metabolic
- 6.1TirzepatideTirzepatide is a once-weekly subcutaneous dual GIP plus GLP-1 receptor agonist with unusually large weight-loss and glycemic effects.
- 6.0MOTS-cMOTS-c is a 16-amino-acid mitochondrial-derived peptide discovered in Lee 2015 that activates AMPK through the folate and purine pathway.
- 6.0TesamorelinTesamorelin is a stabilized GHRH analog that reduced visceral adipose tissue in the landmark Falutz 2007 HIV lipodystrophy Phase 3 trial and has newer support for…
- 5.8CagrilintideCagrilintide (AM833) is a long-acting amylin receptor analogue that drove about 11.8 percent weight loss as monotherapy at 68 weeks in REDEFINE 1 per Garvey 2025, with…
The Ultimate Peptides Guide
Spot stronger candidates, weak evidence, and seller red flags before you buy.